ceralasertib: Clinical Trials

46 trials of ceralasertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 active not recruiting, 10 completed, 7 recruiting, 6 unknown. 31 Phase 2, 14 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 231Active not recruiting 12, Completed 6, Recruiting 6, Unknown 4, Terminated 2, Withdrawn 1
Phase 114Active not recruiting 4, Completed 4, Recruiting 2, Terminated 2, Unknown 2
Phase 32Active not recruiting 2

Follow ceralasertib: new trials by email Literature Review of ceralasertib trials Research Report on ceralasertib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Phase 2RecruitingSWOG Cancer Research Network9002025-11-062026-03-30
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
[14C] AZD6738, AZD6738 / ceralasertib - Neoplasm
Phase 1TerminatedAstraZeneca22025-09-222026-09-03
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3Active not recruitingNational Cancer Institute (NCI)6302025-08-072026-09-21
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Durvalumab (MEDI4736), Ceralasertib, radiotherapy - Non Small Cell Lung Cancer NSCLC
Phase 2RecruitingMario Negri Institute for Pharmacological Research212025-08-072025-12-18
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
Ceralasertib, Drug X, Drug Y - Advanced Solid Tumours
Phase 1TerminatedAstraZeneca12025-05-212026-07-24
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Ceralasertib, Durvalumab - Advanced or Metastatic NSCLC
Phase 2Active not recruitingAstraZeneca392023-06-212026-09-09
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Ceralasertib, Durvalumab, Nab-paclitaxel - Triple Negative Breast Cancer Metastatic
Phase 2RecruitingIFOM ETS - The AIRC Institute of Molecular Oncology372022-12-152025-08-24
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Ceralasertib, Durvalumab - Advanced Solid Tumours
Phase 1Active not recruitingAstraZeneca142022-09-232026-08-11
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Ceralasertib, Durvalumab, Docetaxel - Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3Active not recruitingAstraZeneca5942022-09-152026-07-13
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Ceralasertib, Durvalumab - Melanoma
Phase 2Active not recruitingAstraZeneca1942022-08-112025-07-31
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
Ceralasertib - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca122022-06-092024-08-02
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)512021-08-092026-11-18
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Cisplatin, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Cancer
Phase 2Active not recruitingMuhammad Furqan302021-04-202026-09-03
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390 - Non Small Cell Lung Cancer
Phase 1RecruitingUniversity of Leeds2002021-03-172025-12-19
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
Ceralasertib - Advanced Solid Tumours
Phase 2CompletedAstraZeneca542020-12-012025-08-29
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Olaparib, Ceralasertib - Osteosarcoma, Osteosarcoma Recurrent
Phase 2Active not recruitingDana-Farber Cancer Institute492020-11-242026-09-24
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Olaparib, Ceralasertib, Placebo to match olaparib - Ovarian Cancer
Phase 2WithdrawnAstraZeneca2020-08-072021-03-10
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Cediranib, Ceralasertib, Olaparib - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
Phase 2RecruitingM.D. Anderson Cancer Center602020-07-282026-09-14
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
AZD6738, Durvalumab, Olaparib - Bile Duct Cancer, Chemotherapy Effect
Phase 2UnknownSeoul National University Hospital742020-06-252024-04-19
AZD6738 Plus Durvalumab in Biliary Tract Cancer
AZD6738, Durvalumab - Bile Duct Cancer, Chemotherapy Effect
Phase 2UnknownSeoul National University Hospital262020-06-252024-04-19

Showing 20 of 46. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (7)  ·  Neoplasms (6)  ·  Lung Neoplasms (4)  ·  Triple Negative Breast Neoplasms (4)  ·  Breast Neoplasms (3)  ·  Endometrial Neoplasms (3)  ·  Neoplasm Metastasis (3)  ·  Bile Duct Neoplasms (2)  ·  Carcinosarcoma (2)  ·  Melanoma (2)  ·  Ovarian Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Adenocarcinoma (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)

Sponsors

AstraZeneca (13)  ·  Institute of Cancer Research, United Kingdom (3)  ·  National Cancer Institute (NCI) (3)  ·  Samsung Medical Center (3)  ·  Acerta Pharma BV (2)  ·  M.D. Anderson Cancer Center (2)  ·  Seoul National University Hospital (2)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  CCTU- Cancer Theme (1)  ·  Dana-Farber Cancer Institute (1)  ·  Gordon Mills, MD, PhD (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  IFOM ETS - The AIRC Institute of Molecular Oncology (1)  ·  Joseph Paul Eder (1)  ·  Mario Negri Institute for Pharmacological Research (1)

Countries

United States (22)  ·  United Kingdom (15)  ·  South Korea (10)  ·  France (8)  ·  Spain (8)  ·  Italy (7)  ·  Canada (6)  ·  Germany (5)  ·  Poland (5)  ·  Belgium (3)  ·  Netherlands (3)  ·  Taiwan (3)  ·  Australia (2)  ·  China (2)  ·  Hungary (2)

Top investigators

Alastair Greystoke, MB ChB, MSc, PhD (1)  ·  Andrew M Brunner, MD (1)  ·  Andrew Tutt (1)  ·  Andrew Tutt, MB ChB PhD (1)  ·  Anne C Chiang (1)  ·  Banu Arun (1)  ·  Birgit Geoerger, MD (1)  ·  Corinne Faivre-Finn, MD, PhD (1)  ·  Dr Amit Oza, MD (Lon) FRCP FRCPC (1)  ·  Dr. Umamaheshwar Duvvuri (1)  ·  Duncan Jodrell (1)  ·  Dwight H Owen (1)  ·  Fiona Simpkins, MD (1)  ·  Gary W Middleton (1)

Results publications

PMID 34904813, PMID 31538815, PMID 32379297, PMID 32669708, PMID 32878963, PMID 32919527, PMID 33892407, PMID 33893289, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35790315, PMID 36446040, PMID 37273420, PMID 37934611, PMID 38351187, PMID 40069402, PMID 40525978, PMID 40781023, PMID 41351730, PMID 41686845, PMID 41838385, PMID 42379235, PMID 42518016, PMID 42686334

NIH funding

2016 (3), 2017 (3), 2018 (3), 2014 (1), 2023 (1), U10CA180820 (1), U10CA180888 (1), UM1CA186688 (1), UM1CA186689 (1)